Selegiline in Parkinson's disease
- 16 December 1995
- Vol. 311 (7020) , 1583-1584
- https://doi.org/10.1136/bmj.311.7020.1583
Abstract
In its heyday, the free radical hypothesis fuelled enormous therapeutic trials for Parkinson's disease, based on the premise that if we could reduce formation of free radicals this would confer “neuroprotection” in chronic neurodegenerative disease. The largest of these trials was DATATOP (deprenyl and tocopherol antioxidant therapy for parkinsonism),3 …Keywords
This publication has 11 references indexed in Scilit:
- Comparative study of selegiline plus L‐dopa–carbidopa versus L‐dopa–carbidopa alone in the treatment of parkinson's diseaseAnnals of Neurology, 1995
- Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1993
- The oxidant stress hypothesis in Parkinson's disease: Evidence supporting itAnnals of Neurology, 1992
- The free radical hypothesis in idiopathic parkinsonism: Evidence against itAnnals of Neurology, 1992
- The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomaticAnnals of Neurology, 1992
- Selegiline as initial treatment in de novo parkinsonian patientsNeurology, 1992
- Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMT)Acta Neurologica Scandinavica, 1991
- The Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's DiseaseScience, 1989
- Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm studyJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1985